Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
T Lei, Y Wang, Y Zhang, Y Yang, J Cao, J Huang… - Leukemia, 2024 - nature.com
Abstract Chimeric Antigen Receptor (CAR)-T-cell therapy has revolutionized cancer immune
therapy. However, challenges remain including increasing efficacy, reducing adverse events …
therapy. However, challenges remain including increasing efficacy, reducing adverse events …
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
X Li, T Chen, X Li, H Zhang, Y Li, S Zhang… - … Hematology & Oncology, 2024 - Springer
Chimeric antigen receptor (CAR) T cell therapy, which targets tumors with high specificity
through the recognition of particular antigens, has emerged as one of the most rapidly …
through the recognition of particular antigens, has emerged as one of the most rapidly …
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
RP Patel, G Ghilardi, Y Zhang, YH Chiang, W **e… - Science …, 2024 - science.org
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric
antigen receptor (CAR) T cells eventually experience disease progression. Furthermore …
antigen receptor (CAR) T cells eventually experience disease progression. Furthermore …
Targeting SHP1 and SHP2 to suppress tumors and enhance immunosurveillance
Y Zhao, L Jiang - Trends in Cell Biology, 2024 - cell.com
The nonreceptor tyrosine phosphatases (PTPS) SHP1 and SHP2 have crucial roles in
dephosphorylating an array of substrates involved in pathways comprising receptor tyrosine …
dephosphorylating an array of substrates involved in pathways comprising receptor tyrosine …
[HTML][HTML] HVEM as a Tumor-Intrinsic Regulator in Non-Small Cell Lung Cancer: Suppression of Metastasis via Glycolysis Inhibition and Modulation of Macrophage …
Y Yao, B Li, C Chen, J Wang, F Yao, Z Li - Pharmacological Research, 2025 - Elsevier
Herpes virus entry mediator (HVEM) is a novel costimulatory molecule which mediates
stimulatory or inhibitory signals in immune responses which makes it an attractive target in …
stimulatory or inhibitory signals in immune responses which makes it an attractive target in …
[HTML][HTML] A Novel Prognostic Signature of Mitophagy-Related E3 Ubiquitin Ligases in Breast Cancer
K Bian, C Yang, F Zhang, L Huang - International Journal of Molecular …, 2025 - mdpi.com
Mitophagy plays a critical role in maintaining mitochondrial quality and cellular homeostasis.
But the specific contribution of mitophagy-related E3 ubiquitin ligases to prognoses remains …
But the specific contribution of mitophagy-related E3 ubiquitin ligases to prognoses remains …
Optimising CAR T therapy for the treatment of solid tumors
N Mobark, CM Hull, J Maher - Expert Review of Anticancer …, 2025 - Taylor & Francis
Introduction Adoptive immunotherapy using chimeric antigen receptor (CAR)-engineered T
cells has proven transformative in the management of B cell and plasma cel derived …
cells has proven transformative in the management of B cell and plasma cel derived …
Mécanismes d'action et de résistance aux cellules T à récepteur antigénique chimérique dans les hémopathies B matures
J Ferrant, K Tarte - Hématologie, 2024 - stm.cairn.info
1 Malgré les immenses progrès apportés en hématologie, depuis une vingtaine d'années,
par l'avènement de l'immunochimiothérapie, de nombreux patients restent réfractaires au …
par l'avènement de l'immunochimiothérapie, de nombreux patients restent réfractaires au …